Continuous subcutaneous glucose monitoring shows a close correlation between mean glucose and time spent in hyperglycemia and hemoglobin A1c

Journal of Diabetes Science and Technology

Volumn 1, Issue 6, 2007, Pages 857-863

  Nielsen, Jannik Kruse ^a   Gravholt, Claus Højbjerg ^a   Djurhuus, Christian Born ^a   Brandt, Derek ^b   Becker, Joern ^c   Heinemann, Lutz ^d   Christiansen, Jens Sandahl ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Disetronic Medical Systems AG   (Switzerland)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d Profil Institute for Metabolic Research   (Germany)

Author keywords

Continuous glucose monitoring; Hbalc; Metabolic control; Microdialysis

Indexed keywords

EID: 44249099753     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680700100609     Document Type: Article

References (22)

1. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA. 2006 Apr. 12;295(14):1688-97.
2. Manderson JG, Patterson CC, Hadden DR, Traub AI, Ennis C, McCance DR. Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol. 2003 Aug; 189(2):507-12.
3. Derr R, Garrett E, Stacy GA, Saudek CD. Is HbA (1c) affected by glycemic instability? Diabetes Care. 2003 Oct; 26(10):2728-33.
4. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA (1c). Diabetes Care. 2003 Mar; 26(3):881-5.
5. Tahara Y, Shima K. The response of GHb to stepwise plasma glucose change over time in diabetic patients. Diabetes Care. 1993 Sep; 16(9):1313-4.
6. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997 Dec; 20(12):1822-6.
7. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA (1c): analysis of glucose profiles and HbA (1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002 Feb; 25(2):275-8.
8. Salardi S, Zucchini S, Santoni R, Ragni L, Gualandi S, Cicognani A, Cacciari E. The glucose area under the profiles obtained with continuous glucose monitoring system relationships with HbA (1c) in pediatric type 1 diabetic patients. Diabetes Care. 2002 Oct; 25(10):1840-4.
9. Nielsen JK, Djurhuus CB, Gravholt CH, Carus AC, Granild-Jensen J, Orskov H, Christiansen JS. Continuous glucose monitoring in interstitial subcutaneous adipose tissue and skeletal muscle reflects excursions in cerebral cortex. Diabetes. 2005 Jun; 54(6):1635-9.
10. Meyerhoff C, Bischof F, Sternberg F, Zier H, Pfeiffer EF. On line continuous monitoring of subcutaneous tissue glucose in men by combining portable glucosensor with microdialysis. Diabetologia. 1992 Nov; 35(11):1087-92.
11. Jungheim K, Wientjes KJ, Heinemann L, Lodwig V, Koschinsky T, Schoonen AJ. Subcutaneous continuous glucose monitoring: feasibility of a new microdialysis-based glucose sensor system. Diabetes Care. 2001 Sep; 24(9):1696-7.
12. Kapitza C, Lodwig V, Obermaier K, Wientjes KJ, Hoogenberg K, Jungheim K, Heinemann L; Glucose Monitoring Study Group. Continuous glucose monitoring: reliable measurements for up to 4 days with the SCGM1 system. Diabetes Technol Ther. 2003;5(4):609-14.
13. Clarke WL, Cox D, Gonder-Frederick LA, Carter W, Pohl SL. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care. 1987 Sep-Oct; 10(5):622-8.
14. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm. 1978 Dec; 6(6):539-46.
15. Hassan Y, Johnson B, Nader N, Gannon MC, Nuttall FQ. The relationship between 24-hour integrated glucose concentrations and % glycohemoglobin. J Lab Clin Med. 2006 Jan; 147(1):21-6.
16. Carstensen E, Yudkin JS. Platelet catecholamine concentrations after short-term stress in normal subjects. Clin Sci (Lond). 1994 Jan; 86(1):35-41.
17. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep. 30;329(14):977-86.
18. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Sep. 12;352(9131):854-65.
19. Erratum in: Lancet 1998 Nov. 7;352(9139):1558.
20. Maran A, Crepaldi C, Tiengo A, Grassi G, Vitali E, Pagano G, Bistoni S, Calabrese G, Santeusanio F, Leonetti F, Ribaudo M, Di Mario U, Annuzzi G, Genovese S, Riccardi G, Previti M, Cucinotta D, Giorgino F, Bellomo A, Giorgino R, Poscia A, Varalli M. Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care. 2002 Feb; 25(2):347-52.
21. Rhemrev-Boom RM, Tiessen RG, Jonker AA, Venema K, Vadgama P, Korf J. A lightweight measuring device for the continuous in vivo monitoring of glucose by means of ultraslow microdialysis in combination with a miniaturised flow-through biosensor. Clin Chim Acta. 2002 Feb; 316(1-2):1-10.
22. Tanenberg R, Bode B, Lane W, Levetan C, Mestman J, Harmel AP Tobian J, Gross T, Mastrototaro J. Use of the continuous glucose monitoring system to guide therapy in patients with insulintreated diabetes: a randomized controlled trial. Mayo Clin Proc. 2004 Dec; 79(12):1521-6.